Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
Sepsis, Acute Infection, Organ Failure
About this trial
This is an interventional treatment trial for Sepsis
Eligibility Criteria
Inclusion Criteria: Age >=65 years Primary diagnosis of acute infection (per investigator judgment) SOFA >1 Admission order to the hospital Expected length of stay >=48 hours (per investigator judgment) Exclusion Criteria: Admission to the ICU Vasopressors, mechanical ventilation, or dialysis Comfort care only Total bilirubin >3X or AST/ALT >4x upper limit of normal eGFR < 25 ml/ min/ 1.73 m2 Hemoglobin <7 g/dL; white blood cell count ≤ 2,000/mm3; absolute neutrophil count ≤1 x 10^9/;, or platelet count ≤ 40,000/μL Known HIV, Hepatitis B, or Hepatitis C Invasive fungal infection (per investigator judgment) Uncontrolled effusions or ascites (per investigator judgment) New/active invasive cancer except non-melanoma skin cancers Known hypersensitivity or allergy to Fisetin. Active treatment with potential drug-drug interactions Enrolled in another sepsis clinical trial
Sites / Locations
- University of MinnesotaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
Fisetin- dose 1
Fisetin- dose 2
Placebo
Elderly (>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis, will be given the first dose of fisetin.
Elderly (>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis, will be given the 2nd does of fisetin.
Elderly (>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis will receive placebo treatment.